In 2016 the US based National Transplantation Pregnancy Registry (NTPR) expanded to include participation worldwide and was renamed the Transplant Pregnancy Registry International (TPR). The TPR continues to collect information from female and male solid organ transplant recipients. TPR data are collected via telephone interviews and review of medical records. Participants and live birth outcomes are listed in Tables 1 and 2.
TPR analyses have contributed to clinical recommendations regarding advisability and timing of pregnancy, medications, comorbid conditions and other aspects of post-transplant motherhood. The TPR also serves as a resource for recipients who are making family planning decisions. Pregnancy considerations vary depending on the organ transplanted, but the most significant factors for successful outcomes for mother and child are stable prepregnancy transplant function, avoidance of mycophenolic acid during the 1st trimester, and close follow-up during pregnancy and postpartum. Overall, outcomes of pregnancies fathered by transplant recipients appear similar to those of the general population.
The TPR is a valuable resource for the worldwide transplant community. For many recipients, pregnancy after organ transplantation is possible with the majority of the pregnancies resulting in a healthy live birth. Healthcare providers who counsel transplant recipients regarding family planning and transplant recipients themselves are encouraged to contact the TPR.
Major grant support was provided by Astellas Pharma US, Inc., Bristol-Myers Squibb Company, and Pfizer Inc.